Myriad Genetics Buys Rules-Based Medicine

April 28, 2011

April 28, 2011 | Myriad Genetics has agreed to buy Rules-Based Medicine for $80 million in cash. Rules-Based Medicine works with pharma and biotech partners to develop new biomarkers. It will become a wholly-owned subsidiary of Myriad to be called Myriad RBM. Statesman